Summary The Fas receptor (APO-1/CD95) is capable of inducing apoptosis of lymphoid cells and is expressed in some non-Hodgkin's lymphomas (NHLs). Fas expression is up-regulated at the surface of normal B cells upon triggering of the CD40 receptor. In this report, we investigated the sensitivity of NHLs to Fas-mediated apoptosis induced by anti-Fas monoclonal antibodies (MAbs) and its possible modulation by CD40 ligation in 18 NHL biopsy samples of various histological subtypes. Flow cytometric analysis showed that the fraction of Fas-expressing lymphoma cells was highly variable from sample to sample (from 1% to 93%, mean value 46%). The frequency of apoptotic cells was not significantly increased upon treatment with an anti-Fas MAb compared with control MAb in the 18 NHL cases analysed. The sensitivity of lymphoma cells to Fas-mediated apoptosis was correlated neither with the histological subtypes nor with the level of Fas expression. Activation of neoplastic B cells by CD40 ligation resulted in significant increases in Fas expression and Fas-induced apoptosis among the five B-NHL cases tested. The overall increase in apoptotic rates was moderate and remained lower in tumour samples than in control CD40-activated normal tonsil B cells. Altogether, our results indicate that the sensitivity to Fas-induced apoptosis is null or weak in NHL cells, irrespective of their histological subtype, and that it can be increased to a moderate and variable degree by CD40 ligation on neoplastic B cells. This may be an impediment to the development of Fas-based therapies for NHLs.
Dysregulation of programmed cell death, or apoptosis, can lead to aberrant cell accumulation and is recognized as a possible cause of neoplasia (Korsmeyer, 1992) . The contribution of apoptosis is crucial in the pathogenesis of some non-Hodgkin's lymphomas (NHLs) , such as follicular B-cell NHLs. In this particular NHL type, expression of the Bcl-2 antiapoptotic protein is increased in up to 85% of cases, because of a rearrangement of the BCL-2 gene (Bakhshi et al, 1985) .
The possible influence of apoptosis abnormalities on the growth of other NHL types is still debated. One of the major pathways regulating apoptosis in lymphoid cells appears to be mediated by the Fas antigen (APO-l/CD95), a 45-kDa membrane protein belonging to the tumour necrosis factor receptor (TNFR) superfamily (Itoh et al, 1991; Oehm et al, 1992; Armitage, 1994) . Mice deficient in Fas or its ligand (FasL) are known as Ipr and gld mice respectively (Watanabe-Fukunaga et al, 1992; Lynch et al, 1994) . They develop massive lymphadenopathy, splenomegaly, B-cell activation and autoimmunity owing to unscheduled lymphocyte accumulation (Watanabe-Fukunaga et al, 1992; Lynch et al, 1994) . In addition, Fas has also been demonstrated to act as a tumoursuppressor gene in some particular conditions (Peng et al, 1996) .
Fas is expressed in various human lymphoproliferations (M6ller et al, 1993; Xerri et al, 1995a) , Fas-positive neoplastic cells are sometimes sensitive to Fas-mediated apoptosis induced by anti-Fas monoclonal antibodies (MAbs) or by FasL (Debatin et al, 1990 (Debatin et al, , 1993 Rensingh-Elh et al, 1995) . Injection of anti-Fas MAb into mice carrying lymphoma xenotransplants can induce tumour regression (Coney et al, 1994; Durandy et al, 1997) . The Fas/FasL apoptotic pathway may also play a role in the action of chemotherapeutic drugs (Friesen et al, 1996; Landowski et al, 1997) . Taken together, these observations suggest that Fas may be involved in the regulation of in vivo lymphoma growth and that Fas triggering may be a promising strategy for treatment of NHLs.
Although Fas expression is observed in a variety of neoplasms, Fas-expressing cells are not uniformly sensitive to Fas-mediated signals. Thus, myeloma cells express high Fas levels but do not undergo apoptosis upon treatment with agonistic anti-Fas MAb (Westendorf et al, 1995) . In some cell lines, the degree of resistance to Fas-mediated apoptosis appears to be directly correlated with the level of resistance to chemotherapeutic drugs (Landowski et al, 1997) . The circumstances in which NHLs can resist Fasmediated apoptosis are not fully clarified in the literature. Fas resistance was reported to occur in lymphoma cell lines, and to be modified by CD40 ligation (Schattner et al, 1996) . Like Fas, CD40 belongs to the TNFR superfamily, and regulates B-cell activation and differentiation (Banchereau et al, 1994; Castigli et al, 1996) . CD40 can induce Fas up regulation on the surface of B cells (Schattner et al, 1995) .
Understanding the regulation of Fas-mediated apoptosis therefore appears critical for the development of new therapies against NHLs. In this report we tried to characterize the susceptibility of NHL cells to Fas-induced killing and its possible modulation. We show that Fas resistance frequently occurs in a wide range of B-NHL subtypes, and that CD40 ligation results in a moderate increase in the sensitivity to Fas-mediated cell death. (Dakopatts, Denmark) . Sensitivity of purified cells to Fas-mediated apoptosis was determined as described below. Culture of B cells using the CD40 system was performed as described previously (Garrone et al, 1995; Shultze et al, 1995 (Zhang et al, 1996) . Cellular debris identified on scattergrams and stained by propidium iodide was gated out before quantification, which was performed in a Fas-mediated apoptosis in human lymphomas 227 gate determined after staining with an isotypic control antibody (Immunotech). Cells displaying non-specific reactivity were excluded, and the resulting gate was used for apoptosis quantification using APO.2.7 staining. The efficiencies of apoptotic induction by 7C I I and of immunodetection using APO.2.7 were controlled on Fas-expressing Jurkat cells in all the experiments. In one case the sensitivity to apoptosis of lymphoma B cells was compared with that of the reactive T cells isolated from the corresponding lymphoma tissue.
Detection of apoptotic cells using the anti-7A6 MAb APO2.7 was compared with detection using annexin staining (Annexin kit, Immunotech) in Jurkat cells. The results of both methods were found to be consistent (data not shown). Negative controls were performed by detection of 7A6 on cell populations incubated with an isotype-matched antibody.
RESULTS

FC analysis detects weak to moderate levels of Fas expression on lymphoma cells
The proportion of Fas-positive lymphoma cells was highly variable (mean value 46%) among the 18 lymphoma cases analysed, as detailed in Table 1 . The highest percentage (93%) of Fas expression was detected in a peripheral T-cell NHL (PTL, case 18), The lowest percentages (less than 5%) were observed in one small lymphocytic NHL (SLL, case 13) and one mantle cell NHL (MCL, case 14). The percentages of Fas-expressing cells detected by dual-colour FC analysis in total lymphoma cell populations and by single-colour labeling in purified B-or T-cell subpopulations were in accordance (data not shown). Control Jurkat cells were nearly 100% Fas positive.
Fresh lymphoma cells display null or weak sensitivity to Fas-mediated apoptosis Apoptosis was evaluated by immunodetection of the 7A6 antigen, which defines an epitope on the mitochondrial membrane that becomes exposed on cells undergoing apoptosis (Zhang et al, 1996) . A strict correlation between anti-7A6 positivity on permeabilized cells and levels of apoptosis was reported in peripheral blood lymphocytes and in lymphoid cell lines (Zhang et al, 1996) . In the case of fresh neoplastic B cells, the spontaneous rate of apoptosis after 72 h of culture was significantly higher in B-cell NHLs belonging to the diffuse large-cell subtype (DLCL; mean value 21 %) than in other B-cell NHLs [mean value 9% for follicular NHL (FL) and MCL subtypes, and 7% for SLL].
The difference between the percentages of apoptotic cells in the presence of anti-Fas mAb 7C11 and of a control MAb gives a measure of the relative sensitivity of neoplastic B cells to Fas-mediated cell death. This difference was not significant among the 18 NHL cases analysed at any time point (P > 0.1 using the Student's t-test). Higher concentrations of 7C11 and/or longer incubation periods had no effect on apoptotic rates (Table 1) . No significant difference was observed among the group of 16 B-cell NHLs (P > 0.1), although three samples (cases 1, 8 and 11) showed an increase in the rates of cell death ranging from 11 % to 28% at 72 h (Table 1) . Again, no significant difference in sensitivity was found between the different B-cell NHL subtypes (P > 0.1 for all comparisons). This difference was slightly more pronounced between T-cell NHLs and some B-cell subtypes such as FL and MCL (0.1 > P > 0.05). Similar values were obtained with the control MAb and with medium alone. No correlation could be observed between the levels of Fas expression and the sensitivity to Fas killing in the 18 NHL cases tested (P = 0.412 using the Student's correlation test).
We were able to analyse two cases of T-cell NHL, and they showed very different susceptibilities to 7C11-induced apoptosis. In one case, malignant T cells were almost as sensitive as control Jurkat cells, whereas in the second one they appeared as resistant as neoplastic B cells to 7C 11-induced apoptosis.
CD40 ligation on neoplastic B cells induces CD95 up-regulation and a weak to moderate increase in Fas-induced cell death As indicated in Table 2 , activation of B cells by CD40 ligand resulted in variable increases in Fas expression in the five B-NHL cases analysed ( Figure IA and B) ; the final percentages of Faspositive cells were roughly correlated with the basal levels of Fas expression. A similar increase in Fas expression was observed in normal tonsil B cells upon CD40 ligation (Figure 2) . A 3-day incubation with 7Cl1 MAb significantly increased the rates of apoptosis in CD40-activated neoplastic B cells when compared with incubation with a control MAb (P = 0.008 using the non parametric Mann-Whitney test). CD40 ligation was less efficient in the SLL sample than in the other NHLs tested (Table 2 and Figure 1 A and B). Fas-induced apoptosis appeared higher in tumours displaying high Fas expression after activation. The overall increase in apoptotic rates following CD40 activation remained much lower in tumour samples (mean 23% and maximum 45 §o) than in normal tonsil B cells under the same conditions (71%). Normal B cells showed a low sensitivity to Fas at onset of the culture, but became highly sensitive after CD40 ligation and subsequent Fas up-regulation (Table 2 and Fas-mediated apoptosis in human lymphomas 231
DISCUSSION
The Fas receptor present on the surface of normal activated lymphocytes can trigger their death upon appropriate stimulation (Garrone et al, 1995) . CD40 is a membrane molecule expressed on both normal and malignant B cells (Banchereau et al, 1994) . Binding of its ligand (CD40L) transduces activation and survival signals, and can lead to an increase in Fas expression (Banchereau et al, 1994; Schattner et al, 1995; Castigli et al, 1996) . Normal B cells were reported to be initially resistant to killing via the Fas pathway, and to become sensitive upon CD40 activation, which results in a gradual increase in Fas expression (Garrone et al, 1995; Choe et al, 1996) . We also observed that resting B cells express low (Itoh et al, 1993) . We analysed Bcl-2 expression using reverse transcriptase-polymerase chain reaction (RT-PCR) in the 18 NHL cases, and found no correlation between the level of expression and the sensitivity to Fas killing (data not shown). These results do not exclude a possible role of other members of the Bcl-2 family, such as Bcl-xL, which was demonstrated to decrease Fas killing when transfected into apoptosis-sensitive myeloma cells (Gauthier et al, 1996) ; we reported previously that the majority of human NHLs express substantial amounts of Bcl-xL (Xerri et al, 1996) . The defect could be linked alternatively to the effectors of apoptosis including caspases, which are known to control the distal point of a common apoptotic pathway shared by many cell death inductors (Casciola-Rosen et al, 1996; Henkart, 1996) . Among caspases, CPP32 seems to play a particular role in the lymphoid system, as it is expressed, as an inactive precursor (pro-CPP32), in germinal centres and in some NHLs (Krajewski et al, 1997; Xerri et al, 1997) . Dysfunction in the CPP32 activating pathway thus cannot be ruled out. Further investigations are required to unravel the respective roles played by the ever increasing number of molecules involved in apoptosis.
One can also speculate that the primary structure of Fas is altered in lymphoma cells, thus rendering the molecule inactive. Structural defects have been identified in some Fas-resistant cell lines that harbour a truncated Fas molecule (Cascino et al, 1996) . Our previous search for rearrangements and/or deletions of the Fas gene in a large series of human lymphoma samples did not reveal a frequent occurrence of such abnormalities (Xerri et al, 1995b) , although the presence of point mutations cannot be ruled out.
Our results on NHLs slightly differ from those of Schattner et al (1996) , who recently reported that four out of six Burkitt's lymphoma (BL) cell lines and one fresh BL sample manipulated by T cells expressing CD40L were rendered highly susceptible to Fas-mediated cytolysis. Nonetheless, it is possible that the susceptibility to Fas-induced apoptosis of BL cells differs from that of other B-cell NHLs, as BL appears to be antigen driven (Jain et al, 1994) , and as engagement of the antigen receptor interferes with apoptosis on B-cells (Choe et al, 1996) . Another possibility is that cytokines produced by T cells are required to prime neoplastic B cells optimally for Fas-induced apoptosis. Wang et al (1997) reported a moderate increase in Fas-induced cell death after CD40 activation in nine out of ten NHLs; the apoptotic rates reported in the later study were higher than in the present one. This difference may be due to the addition of interleukin 4 (IL-4) during CD40 stimulation. However, our findings are in close agreement with a more recent report (Plumas et al, 1998) in which the addition of IL-4 during CD40 stimulation was shown to have no significant influence on Fas-induced lymphoma cell death.
Finally, this report establishes that resistance to Fas-induced apoptosis is a widespread phenomenon in B-cell NHLs, irrespective of their histological subtype, whereas susceptibility of T-cell NHLs appears more heterogeneous and needs to be further investigated. In addition, CD40 activation of human malignant B cells seems not able to circumvent completely the resistance to Fas killing; Fas-based therapies may only be applicable to a restricted number of NHLs. The mechanisms underlying the resistance of NHL cells to apoptosis must be further clarified before a therapeutic strategy can be elaborated.
